VOA常速英语:Antibiotic Rejuvenation Could Outsmart Superbugs

Bacteria have been developing resistance to antibiotics, almost as long as we have been making antibiotics,according to Anthony Coates, founder of Helperby Therapeutics.
细菌一直在对抗生素产生耐药性，就像我们一直在制造抗生素一样，据Helperby医疗公司的创始人安东尼·科茨说。
“The human race made a huge mistake between the 1940s to the 1970s.We produced about 20 new classes of antibiotics with about 200 analogs.And we thought that was enough then we stopped making antibiotics, but bacteria became resistant to all of them.We mustn’t fall into that trap again.We must produce our new antibiotics gradually in combinations.”Creating combinations is how Helperby is rejuvenating old antibiotics, like colistin.
人类在20世纪40年代到70年代之间犯了一个巨大的错误。 我们制造了大约200种类似物的20多种新类抗生素。 我们认为这些已经足够了，于是停止制作抗生素，但是现在细菌已经对现有抗生素有了抗药性。我们不能重蹈覆辙，必须联合逐步生产新的抗生素。该公司采用创造性的结合方法使黏菌素类的古老的抗生素重新焕发生机。
Colistin is the last resort antibiotic against CRE (carbapenem-resistant Enterobacteriaceae),which causes severe and often fatal infections, and is starting to show resistance in China and parts of Southeast Europe.Coates calls CRE the bug that may end modern medicine.
黏菌素是现存唯一一种对耐碳青霉烯类肠杆菌(CRE)有效果的抗生素，通常CRE会引发严重感染，这种病毒已经在欧洲东南部和中国表现出抗药性。科茨把CRE称作现代医学的漏洞。
“And you can see in this control plate that they grow very nicely into little colonies.”Combining these booster drugs with existing antibiotics,give them the power to puncture the tough cell wall of CRE and other evolving superbugs, allowing them to effectively do their work.
你可以在这个对照组培养皿上看到它们很好地长成小菌落。将这些加强型药物与现有的抗生素相结合，让他们能够穿透CRE和其他不断变化的超级细菌的坚硬细胞壁，使它们能够有效地发挥作用。
“And when we add the new antibiotic, you can see the effect, there are no bacteria growing at all.”By introducing a new booster every 30 years or so, Coates believes they can stay one step ahead of bacterial resistance and future-proof.Colistin and the other of last resort drugs in our medical arsenal.
当我们添加新的抗生素时，你可以看到效果，根本没有细菌生长。通过每三十年左右引入一种加强型细菌，科茨相信他们始终可以领先细菌的抗药性一步，并且能够做到提前预防。黏菌素和其他储备药物都是我们对抗病毒的武器库。
I’m Faith Lapidus VOA News.
我是VOA记者菲斯。